Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination

2019/05/31 by Lauri E. Markowitz, Allison L. Naleway, Rayleen M. Lewis +5 · 26 citations
Medicine · #Cervical Cancer and HPV Research #Lymphadenopathy Diagnosis and Analysis #Endometrial and Cervical Cancer Treatments

paper · doi:10.1016/j.vaccine.2019.04.099

Cited by

• Population-Level Effectiveness and Herd Protection 17 Years After HPV Vaccine Introduction
• Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses. [europepmc]
• Evaluation of a Text Messaging-Based Human Papillomavirus Vaccination Intervention for Young Sexual Minority Men: Results from a Pilot Randomized Controlled Trial. [europepmc]
• Prevalence of human papillomavirus genotypes in high-grade cervical precancer and invasive cervical cancer from cancer registries before and after vaccine introduction in the United States. [europepmc]
• Overview of virus and cancer relationships. Position paper. [europepmc]
• Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and Young Women Immunized With the Human Papillomavirus Vaccine. [europepmc]
• Prevention and Screening of HPV Malignancies. [europepmc]
• The impact of HPV vaccination beyond cancer prevention: effect on pregnancy outcomes. [europepmc]
• Nudging toward vaccination: a systematic review. [europepmc]
• Latinx Immigrant Mothers' Perceived Self-Efficacy and Intentions Regarding Human Papillomavirus Vaccination of Their Daughters. [europepmc]
• Changes in Cervical Cytology Results and Human Papillomavirus Types Among Persons Screened for Cervical Cancer, 2007 and 2015-2017. [europepmc]
• Test Performance of Cervical Cytology Among Adults With vs Without Human Papillomavirus Vaccination. [europepmc]
• Ubiquitin specific peptidase 11 as a novel therapeutic target for cancer management. [europepmc]
• Value of TCT combined with serum CA153 and CA50 in early diagnosis of cervical cancer and precancerous lesions. [europepmc]
• Knowledge of cervical cancer prevention and treatment, and willingness to receive HPV vaccination among college students in China. [europepmc]
• The Burden of Cervical Conization in Privately Insured Young and Mid-Adult Women in the United States. [europepmc]
• Vaccine and Non-Vaccine HPV Types Presence in Adolescents with Vertically Acquired HIV Five Years Post Gardasil Quadrivalent Vaccination: The ZIMGARD Cohort. [europepmc]
• Cervical cancer screening barriers and facilitators from the perspectives of women with a history of criminal-legal system involvement and substance use. [europepmc]
• Assessing the reduction of viral infectivity in HPV16/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol. [europepmc]
• Effect of vaccine hesitancy on female college students' willingness to receive the HPV vaccine in China: a multicenter cross-sectional study. [europepmc]
• Effectiveness of Catch-Up Vaccination Interventions Versus Standard or Usual Care Procedures in Increasing Adherence to Recommended Vaccinations Among Different Age Groups: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Before-After Studies. [europepmc]
• The Future of Cervical Cancer Screening. [europepmc]
• The indirect effect of the bivalent human papillomavirus vaccination program: an observational cohort study. [europepmc]
• High-risk human papillomavirus infection (HPV 16/18) and its determinants among women in East Gojjam Zone, Northwest Ethiopia: a population-based cross-sectional study, 2021. [europepmc]
• Population-Level Effectiveness and Herd Protection 17 Years After HPV Vaccine Introduction. [europepmc]
• Variations in the Natural History of High-Risk HPV Types Following HPV-16/18 Bivalent Vaccination in Females Aged 18-45 Years. [europepmc]